Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To investigate Risperidone associated with an increased fracture risk by estimating the incidence of hip/femur and nonhip/femur fractures in users

Trial Profile

To investigate Risperidone associated with an increased fracture risk by estimating the incidence of hip/femur and nonhip/femur fractures in users

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2018

At a glance

  • Drugs Risperidone (Primary)
  • Indications Aggression; Dementia; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Sep 2018 New trial record
    • 26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top